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a  b  s  t  r  a  c  t
Introduction:  The  ongoing  pandemic  of  the  coronavirus  disease  2019  (COVID-19)  is a  global  health  con-
cern. It has  affected  more  than  5 million  patients  worldwide  and  resulted  in  an  alarming  number  of deaths
globally.  While  clinical  characteristics  have  been  reported  elsewhere,  data  from  our  region  is  scarce.  We
investigated  the  clinical  characteristics  of  mild  to  moderate  cases  of  COVID-19  in  Saudi  Arabia.
Methods:  This  is  a descriptive,  cross-sectional  study.  Data  of  401  confirmed  COVID-19  patients  were
collected  from  22  April  2020  to 21  May  2020  at five  tertiary  care  hospitals  in Riyadh,  Saudi  Arabia.  The
patients  were  divided  into  four  groups  according  to  age,  Group  1: 0–<18  years,  Group  2:  18–<50  years,
Group  3: 50–60  years,  and  Group  4: >60  years;  and  their  clinical  symptoms  were compared.
Results:  The  median  (IQR)  age  in  years  was 10.5  (1.5−16)  in group  I, 34  (29−41)  in  group  II, 53  (51−56)
in  group  III, and  66  (61−76)  in group  IV.  Most  patients  were  male  (80%,  n  =  322)  and  of  Arabian  or
Asian  descent.  The  median  length  of  stay  in the  hospital  was  10 (8–17)  days  (range  3–42  days).  The
most  common  symptoms  were  cough  (53.6%),  fever  (36.2%),  fatigue  (26.4%),  dyspnea  (21.9%),  and  sore
throat  (21.9%).  Hypertension  was  the  most common  underlying  comorbidity  (14.7%),  followed  by  obesity
(11.5%),  and  diabetes  (10%).  Hypertensive  patients  were  less  likely  to present  with  shortness  of breath,
cough,  sputum,  diarrhea,  and  fever.
Conclusion:  There  was  no  significant  difference  in  the  symptoms  among  different  age  groups  and  comor-
bidities  were  mostly  seen  in  the  older  age  group.  Interestingly,  hypertensive  patients  were  found  to have
milder  symptoms  and  a shorter  length  of  stay.  Further  larger  collaborative  national  studies  are  required
to  effectively  understand  clinical  characteristics  in our part  of the world  to  efficiently  manage  and  control
the  spread  of  SARS-CoV-2.
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Introduction
In early December 2019, an outbreak of pneumonia cases caused
by an unknown pathogen was reported from Wuhan, China [1].
With the aid of real-time reverse transcription-polymerase chain
reaction (RT-PCR) and next-generation sequencing from their res-
piratory tracts, researchers isolated a novel strain of coronavirus
[2]. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
was the unearthed strain of coronavirus causing the contagious res-
piratory illness, which was later named coronavirus disease 2019
(COVID-19). The causative agent was then named Severe Acute
Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). On compara-
tive modeling, SARS-CoV-2 showed a 79% phylogenetic similarity
to SARS-CoV, with a comparable receptor-binding domain (ACE2)
[2]. Initial cases were thought to be linked to a large livestock and
seafood market selling different wild animal species, suggesting
zoonotic transmission [3]. However, the epidemiology of the dis-
ease then changed to sustained human-to-human transmission of
the virus [4].
Since the outbreak, the disease has spread rapidly across the
globe, resulting in a worldwide COVID-19 pandemic. According
to the World Health Organization (WHO), as of August 22, 2020,
22,812,491 confirmed cases of COVID-19 have been recorded
worldwide, with 795,132 deaths [5]. In the Kingdom of Saudi Ara-
bia, the Ministry of Health confirmed the first COVID-19 positive
case on March 2, 2020 [6]. Till now, 306,370 confirmed cases have
been recorded and 3619 individuals have died in the Kingdom [7].
Although it is difficult to assess the case fatality rate of COVID-19
before the pandemic is over, the available data suggests that China
has a case-fatality rate of 5.5%, France with 25.4%, United Kingdom
with 14.2%, Italy with 14.4%, Brazil with 5.6%, United States of Amer-
ica with 5.8%, and Saudi Arabia presently has a case-fatality rate of
0.6% [8]. This may  be due to locally prevalent factors (including
recent exposure to the Middle East respiratory syndrome corona-
virus (MERS-CoV) epidemic [9] and endemicity of malaria) and the
multiple prompt measures taken by the government of Saudi Ara-
bia to control the spread of the virus. Worldwide, COVID-19 has a
significantly higher case fatality rate than influenza (0.1%), compa-
rable to SARS (10%), but lower than the MERS-CoV (34%) [9,10].
Given the rapid spread of COVID-19 and the sparse data from our
region, here we describe the results of our analysis of the epidemi-
ological and clinical characteristics of COVID-19 patients admitted
at five private tertiary care hospitals in Saudi Arabia.
Methods and materials
Study design
This descriptive, cross-sectional study was conducted at the
five private tertiary care hospitals in Riyadh, Saudi Arabia (Dr.
Sulaiman Al-Habib Medical Group’s hospitals (As-Suwaidi, Rayan,
Al-Takhassusi, Olaya) and Al-Hammadi hospital). All admitted
patients with confirmed COVID-19 from 22/4/2020 to 21/05/2020
were enrolled in the study. We  used a cross-sectional study design
to assess the burden of mild and moderate COVID-19 cases in the
Saudi population.
Data collection
A predesigned and unified data collection form was  designed
to collect pre-specified data variables from non-ICU patients’
electronic medical records by trained physicians. The study was
approved by Dr. Sulaiman Al Habib Medical Group Institutional
Review Board, reference number (RC20.04.79). All the data col-
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emographics, comorbidities, clinical signs or symptoms, were all
btained through the data collection form. The diagnosis of COVID-
9 was  based on the Novel Corona Virus (2019-nCoV) Infection
uidelines issued by the Ministry of Health of Saudi Arabia.
The study population was  divided into four age groups:
Group 1: 0–<18 years
Group 2: 18–<50 years
Group 3: 50–60 years
Group 4: >60 years
We  also compared the clinical characteristics between dia-
etic patients and non-diabetics, hypertensive patients and
on-hypertensive patients.
efinitions
Patients’ severities were classified based on the “Chinese Clin-
cal Guidance for COVID-19 Pneumonia Diagnosis and Treatment”
ublished by the World Health Organization. “Mild” was defined
s mild clinical symptoms or asymptomatic with no signs of
neumonia in imaging; and “Moderate” was  defined as having
ever or respiratory tract symptoms and signs of pneumonia in
maging [11]. Hypertension was  defined as an elevated blood
ressure (SBP > 120 or DBP > 80) Diabetes mellitus was  defined
s hemoglobin A1c > 6.5% (>48 mmol/mol), Fasting Blood Glu-
ose > 126 mg/dL (>7.0 mmol/L), 2-h postprandial > 200 mg/dL
>11.1 mmol/L) during 75-mg OGTT or Random plasma glucose >
00 mg/dL (>11.1 mmol/L) in a symptomatic patient. Cardiolog-
cal disease was  defined as patients with involved heart and/or
lood vessels condition other than hypertension, such as coronary
eart diseases, stroke, heart failure, cardiomyopathy, atrial fibril-
ation, arrhythmia, Marfan’s syndrome, venous thromboembolism,
eripheral arterial disease, heart valve diseases, aortic aneurysms,
nd congenital heart diseases. Respiratory Disease was defined
s patients with diagnosed chronic respiratory diseases, such
s chronic obstructive pulmonary disease (COPD), emphysema,
sthma, acute/chronic bronchitis, pulmonary fibrosis, pneumonia,
ung cancer, occupational lung disease, and pulmonary hyperten-
ion. Chronic kidney disease was defined as patients with identified
hronic kidney disease (CrCl <15 ml/min for >3 months). Dyslipi-
emia was  defined as total cholesterol ≥200 mg/dL, LDL-C ≥ 100
g/dL, triglycerides ≥150 mg/dL, or HDL-C ≤40 mg/dL in males
nd ≤50 mg/dL in females. Immunodeficiency was defined as sub-
ects with any identified congenital or acquired immunodeficiency
e.g., common variable immunodeficiency, human immunodefi-
iency virus (HIV) infection, organ transplantation). Adult obesity
as defined as BMI  30.0 or above. It was further subdivided into
lass I: BMI  of 30.0 to <35.0/Class II: BMI  of 35.0 to <40.0/Class III
MI  of 40.0 or higher. Childhood Obesity was  defined as BMI  at or
bove the 95th percentile for children and teens of the same age
nd sex. Pregnancy was defined as clinically tested by the detec-
ion of hCG in the sample. Smoking was  defined as an adult who
as smoked 100 cigarettes in his or her lifetime and who currently
mokes cigarettes. The hospital length of stay was  defined as the
eriod between the date of admission to the date of discharge or
he date of transfer to another hospital; patients still admitted to
he hospital were excluded from the calculation of the length of
tay.
tatistical analysis
Data were analyzed using SPSS (V.24.0). A value of p < 0.05 was
onsidered statistically significant. Distribution of the continuous
ariables was  carried out by the Shapiro–Wilk test. Frequencies
nd percentages were calculated for categorical variables. The 2
est was applied to examine categorical data. Chi-square test was
lso employed to detect the relationship between the categorical
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Table  1
Comparison of demographics between age groups (n = 401).
Variable Group I Group II Group III Group IV P-value
(0–<18y) (18–<50y) (50y–60y) (>60y)
n  = 16 n = 309 n = 51 n = 25
Age 10.5 (1.5−16) 34 (29−41) 53 (51−56) 66 (61−76)
<0.0001Median (IQR); Range 7mon–17y 19–49y 50–58y 60–88y
Gender
Male 15 (93.8%) 250 (80.9%) 38 (74.5%) 18 (72%)
0.26Female 1 (6.3%) 59 (19.1%) 13 (25.5%) 7 (28%)
Smoking
Non-smoker 16 (100%) 282 (91.3%) 49 (96%) 23 (92%)
<0.0001Smoker – 21 (6.8%) 2 (4%) 2 (8%)
Former smoker – 6 (1.9%) – –
Description of
Hospital Stay
Still 13 (81.3%) 241 (78%) 44 (86.3%) 17 (68%)
0.321Transferred 1 (6.3%) 14 (4.5%) 0 3 (12%)
Discharged 2 (12.5%) 54 (17.5%) 7 (13.7%) 5 (20%)
Hospital Length of Stay (transferred/discharged) 5 9.5 (8−16.75) 20 (11−24) 12 (7.75–16.75) 0.027
Severity
Mild 10 (62.5%) 171 (55.3%) 40 (78.4%) 20 (80%)
0.003Moderate 6 (37.5%) 138 (44.7%) 11 (21.6%) 5 (20%)
mally distributed data. A p-value of <0.05 is considered significant.
Table 2
Clinical characteristics of the study population.






Shortness of breath 88 (21.9%)
Muscle pain 58 (14.5%)
Joint pain 37 (9.2%)








Sputum production 31 (7.7%)
Hypertension 60 (14.7%)
Diabetes 41 (10.0%)
Cardiologic diseases 11 (2.7%)
Respiratory disorders 15 (3.7%)




Not obese 355 (88.5%)













Frequencies & Percentages are given for categorical data; Median (IQR) for non-nor
The  bold values are the significant p-values that are <0.05.
variables. The chi square test was used to compare the clinical char-
acteristics between hypertension and non-hypertensive groups
and diabetes and non-diabetic groups. We  calculated length of
stay from the date of admission to date of discharge/transfer. The
median (IQR) length of stay is given for all. Then we  analyzed
according to age groups and calculated the median (IQR) length
of stay of each age group. These medians were compared using
Kruskal–Wallis test. Then we analyzed the length of stay according
to hypertension or no hypertension, gave median (IQR) of both and
compared medians using Mann–Whitney U test. Then we analyzed
according to diabetes or no diabetes, gave median (IQR) of both
groups and compared medians using Mann–Whitney U test.
Results
The current study included 401 patients who had a confirmed
diagnosis of COVID-19 from a non-intensive care unit setting. None
of the patients died and none of them previously had either MERS-
CoV or SARS-CoV. The age ranged from 7 months to 88 years and
was divided into four age groups. There were 16 (4%) in Group I, 309
(77%) in Group II, 51 (12.7%) in Group III, and 25 (6.3%) in Group IV).
The median (IQR) age was 10.5 (1.5−16) in group I, 34 (29−41) in
group II, 53 (51−56) in group III, and 66 (61−76) in group IV. The
majority of our patients were male (80%, n = 322), as compared to
females (20%, n = 80), and of those only one was pregnant. Gender
was similar across all age groups with a male to female ratio of 4:1
in the total population. The patients were mostly of Arabian and
Asian descent (48.4% and 49.6% respectively), with a few patients of
African (1.2%), Turkish (0.2%), and American (0.5%) descent. Among
these patients, the severity of the patients was mostly mild (60.1%)
to moderate (39.9%).
Most patients (92.3%, n = 370) were non-smokers, 23 (5.7%) were
smokers and 8 (2%) were former smokers. The mean length of stay
in the hospital was 12.26 ± 6.79 days (range 3–42 days). Moreover,
315 (78.6%) of the study population was admitted to the ward, 4.5%
(18) were transferred to government hospitals and 68 (17%) were
discharged. The difference in the length of hospital stay across the
age groups was significant (Table 1).
Clinical characteristics are depicted in Table 2. The most com-
mon  symptoms were cough (53.6%), fever (36.2%), fatigue (26.4%),
dyspnea (21.9%), sore throat (21.9%), headache (16.2%), muscle pain
(14.5%), joint pain (9.2%), sputum production (7.7%), and diarrhea
(7.7%). Comorbidities were present in 112 (27.9%) patients, with
hypertension being the most common (14.7%), followed by obesity





Class II 10 (2.5%)
Class III 2 (0.5%)
Amongst the clinical symptoms, only sputum production dif-
ered across age groups, with the highest incidence in group IV (25%
s. 6.3–8.9%). Comorbidities such as hypertension, diabetes, cardi-
logical disorders, and dyslipidemia were also more prevalent in
roup IV. There was  only one patient each of chronic kidney dis-
ase and immunodeficiency in our study population. Obesity was
imilar across all the age groups. The comparison of the clinical
haracteristics across the age groups is shown in Table 3.
Of all patients, 60 (14.7%) had hypertension. Clinical symptoms
n hypertensive and non-hypertensive patients are given in Table 4.
nterestingly, patients with a history of hypertension were less
ikely to present with shortness of breath, cough, sputum, and fever.
here was  a significant difference (p = 0.033) in the hospital length
f stay between hypertensive and non-hypertensive patients: 14
ays (IQR 9–22) versus 10 days (IQR 8–15) respectively.Of all patients, 41 (10.0%) had diabetes. Clinical characteris-
ics in diabetic and non-diabetic patients are detailed in Table 5.
ll clinical symptoms were more prevalent in diabetic patients as
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Table  3
Comparison of clinical characteristics between the age groups (n = 401).
Clinical characteristic Group I Group II Group III Group IV P-value
(0-<18y) (18-<50y) (50y-60y) (>60y)
n  = 16 n = 309 n = 51 n = 25
Fever 5 (31.3%) 106 (34.3%) 24 (42.9%) 10 (50.0%) 0.337
Cough 6 (37.5%) 162 (52.4%) 32 (57.1%) 15 (75.0%) 0.122
Fatigue 3 (18.8%) 81 (26.2%) 13 (23.2%) 9 (45.0%) 0.227
Headache 3 (18.8%) 53 (17.2%) 4 (7.1%) 5 (25.0%) 0.187
Diarrhea 4 (25.0%) 26 (8.4%) 1 (1.8%) – 0.10
Shortness of Breath 3 (18.8%) 60 (19.4%) 19 (33.9%) 6 (30.0%) 0.082
Muscle Pain 1 (6.3%) 49 (15.9%) 6 (10.7%) 2 (10.0%) 0.509
Joint  Pain 1 (6.3%) 31 (10.0%) 5 (8.9%) – 0.485
Sore  Throat 1 (6.3%) 73 (23.6%) 11 (19.6%) 3 (15.0%) 0.315
Rhinorrhea 1 (6.3%) 23 (7.4%) 4 (7.1%) 1 (5.0%) 0.979
Anosmia 1 (6.3%) 15 (4.9%) 2 (3.6%) 1 (5.0%) 0.967
Dysgeusia 1 (6.3%) 17 (5.5%) 3 (5.4%) 1 (5.0%) 0.999
Hyposmia – 3 (1%) – – 0.825
Anorexia 1 (6.3%) 9 (2.9%) 2 (3.6%) 1 (5.0%) 0.853
Nausea 1 (6.3%) 24 (7.8%) 2 (3.6%) – 0.413
Vomiting 2 (12.5%) 14 (4.5%) 1 (1.8%) – 0.215
Sputum Production 1 (6.3%) 20 (6.5%) 5 (8.9%) 5 (25.0%) 0.027
Hypertension 1 (6.3%) 27 (8.7%) 23 (41.1%) 9 (45.0%) <0.0001
Diabetes – 17 (5.5%) 14 (25.0%) 10 (50.0%) <0.0001
Cardiological Diseases – 3 (1.0%) 3 (5.4%) 5 (25.0%) <0.0001
Respiratory Disorders 1 (6.3%) 8 (2.6%) 3 (5.4%) 3 (15.0%) 0.031
Chronic Kidney Disease 1 (6.3%) – – – <0.0001
Dyslipidemia – 6 (1.9%) 6 (10.7%) 7 (35.0%) <0.0001
Immunodeficiency – 1 (0.3%) – – 0.960
Obesity
No  14 (87.5%) 274 (88.7%) 45 (88.2%) 22 (88.0%)
0.995
Class  I 2 (12.5%) 25 (8.1%) 5 (9.8%) 2 (8.0%)
Class II – 8 (2.6%) 1 (2.0%) 1 (4.0%)
Class III – 2 (0.6%) – –
Frequencies and percentages are given for categorical data; Median (IQR) for non-normally distributed data. A p-value of <0.05 is considered significant.
The  bold values are the significant p-values that are <0.05.
Table 4
Clinical characteristics of hypertensive and non-hypertensive patients.
Clinical Characteristics Patients with hypertension Patients without hypertension P-Value
Fever 29 (20%) 116 (80%) 0.025
Cough 39 (18.1%) 176 (81.9%) 0.05
Fatigue 21 (19.8%) 85(80.2%) 0.10
Headache 9 (13.8%) 56 (86.2%) 0.78
Diarrhea 8 (25.8%) 23 (74.2%) 0.07
Shortness of breath 24 (27.3%) 64 (72.7%) 0.0001
Muscle pain 9 (15.5%) 49 (84.5%) 0.89
Joint  pain 5 (13.5%) 32 (86.5%) 0.79
Sore  throat 11 (12.5%) 77 (87.5%) 0.46
Rhinorrhea 4 (13.8%) 25 (86.2%) 0.85
Anosmia 2 (10.5%) 17 (89.5%) 0.57
Dysgeusia 4 (18.2%) 18 (81.8%) 0.66
Hyposmia 0 (0%) 3 (100%) 0.46
Anorexia 3 (23.1%) 10 (76.9%) 0.40
Nausea 6 (22.2%) 21 (77.8%) 0.27











Sputum production 10 (16.7%) 
The bold values are the significant p-values that are <0.05.
compared to non-diabetic patients, with a statistically significant
difference in fatigue, diarrhea, shortness of breath, and sputum pro-
duction. The average hospital length of stay did not differ between
diabetic patients and non-diabetics: 9 days (IQR 5–17) versus 10
days (IQR 8–17) respectively (p = 0.56).
Discussion
This study summarizes the demographics and clinical charac-
teristics of COVID-19 patients admitted at five private tertiary care
hospitals in Riyadh, Saudi Arabia. We  wanted to highlight the pres-
ence of COVID-19 features in very young people, especially in Saudi
Arabia, as some studies around the world are suggesting above 50







igh-risk factor [12–16]. The age range of our patients varied from 7
onths to 88 years, which indicates that all age groups are suscep-
ible to COVID-19. However, 77% were between 18 and <50 years
f age, and only 16 were under the age of 18. Wei  et al. reported
ine infected infants of which seven were female, and four of them
resented with fever [17]. More recently, a larger study was con-
ucted on the pediatrics population indicating that most of the
atients were either asymptomatic, mild, or moderate cases with
ime from illness onset to diagnoses range of 0–42 days [18]. Our
tudy concurs with these studies that younger age is not immune to
OVID-19 susceptibility. We  should be cautious as children being
ess symptomatic would usually not present to the hospital. They
ay be more prevalent in society as asymptomatic carriers and
ay  contribute to spreading COVID-19.
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Table  5
Clinical features in diabetic versus non-diabetic patients.
Characteristics Patients with diabetes Patients without diabetes P-Value
Fever 129 (89%) 16 (11%) 0.68
Cough 189 (87.9%) 26 (12.1%) 0.184
Fatigue 88 (83%) 18 (17%) 0.007
Headache 57 (15.8%) 8 (19.5%) 0.54
Diarrhea 24 (77.4%) 7 (22.6%) 0.018
Shortness of breath 72 (81%) 16 (18.2%) 0.005
Muscle pain 49 (84.5%) 9 (15.5%) 0.15
Joint  pain 30 (81.1%) 7 (18.9%) 0.06
Sore throat 81 (92%) 7 (8%) 0.42
Rhinorrhea 26 (89.7%) 3 (10.3%) 0.92
Anosmia 18 (94.7%) 1 (5.3%) 0.46
Dysgeusia 19 (86.4%) 3 (13.6%) 0.58
Hyposmia 3 (100%) 0 0.55
Anorexia 12 (92.3%) 1 (7.7%) 0.75
Nausea 24 (88.9%) 3 (11.1%) 087







































Sputum production 21 (67.7%) 
The bold values are the significant p-values that are <0.05.
The median age of the included patients in this study was 36
(IQR: 30–45) years, while other studies had an older population
with median ages ranging from 37 to 70.5 years [15,16]. This is
identical to the only other published study of the Saudi popula-
tion which showed the median age of all COVID-19 patients was
36 years [19]. From the Middle East, a study of 63 patients from
Oman showed a mean age of 48 ± 16 years [20]. Most of our
patients were also men  (female to male ratio 1:4) which is in
concordance to the published literature from China, the United
States, and the United Kingdom [15,16,21–24]. As seen in studies
for MERS-CoV and SARS-CoV, SARS-CoV-2 is more likely to infect
adult men  [9,25]. This might be due to the X chromosome and
sex hormones present in women that play a protective role (via
innate and adaptive immunity) in susceptibility to viral infections
[26].
SARS-CoV-2 has an incubation period of 1–14 days and multi-
ple studies have reported that patients mostly present with fever,
cough, sputum, and fatigue [15,16,22,27]. The estimated median
incubation period of SARS-CoV-2 was recently reported to be 6 days
in Saudi Arabia [19]. Concordantly, in our study, the most common
presenting symptoms were cough, fever, and fatigue. It is impor-
tant to note that Alsofayan et al. also reported that cough and fever
were the most common symptoms in the Saudi population, with
the only difference being high prevalence of sore throat (81.6%)
[19]. Although sputum production seemed to be increasing with
age, generally it was a less frequently occurring symptom in our
study population. This may  be due to the fact that the majority of
our patients were lesser than the age of 60 years, in contrast to other
studies [15,16,21,22,24]. The prevalence of cough was  also more in
older age groups, however, the difference across age groups was
not statistically significant. In addition, gastrointestinal symptoms
were also present in our patients including diarrhea (7.7%), nausea
(6.7%), and vomiting (4.3%).
MERS-CoV had shown to survive in the gastrointestinal juice and
up to 30% of MERS-CoV patients had diarrhea [28,29]. There have
been reports showing the presence of SARS-CoV-2 in stool samples
of asymptomatic and symptomatic patients [30,31]. A recent study
concluded that patients with digestive symptoms were more likely
to be fecal virus positive (73.3% vs 14.3%, P = 0.033) than those with
respiratory symptoms, and with a longer interval between symp-
tom onset and viral clearance (P < 0.001) [32]. Hence, we  should
not neglect patients with gastrointestinal symptoms and we may
test their stool samples for viral RNA to reduce false-negative diag-
noses.
Consistent with previous studies, hypertension was  the most







15,19,20,22,33]. We  need to be persistently vigilant because 67.9%
f the deceased COVID-19 patients in Italy had hypertension [34].
owever, our findings showed that hypertensive patients had
ilder symptoms and a shorter length of stay. The reason for this
s unclear as history of angiotensin-converting enzyme inhibitor
r angiotensin II receptor blockers use has exceptionally low evi-
ence in predicting outcomes in COVID-19 [35]. Other common
omorbidities seen were cardiovascular disease, and dyslipidemia,
hich were also higher in group IV of our patients. Contrary to
ur findings, Docherty et al. reported a large group of patients
n the UK which had chronic pulmonary and kidney diseases as
ajor comorbidities [24]. Additionally, obesity was recorded in
1.5% of our patients, which was not described in the recent study
f the Saudi population [19]. Obesity is a growing health concern
n the Saudi population and an underappreciated risk factor for
OVID-19 as depicted in data from the United States [36,37]. Young
bese COVID-19 patients may  be at risk of disease progression as
bese patients can potentially have impairment of ventilation with
estrictive diaphragmatic and rib mobility, along with an impaired
mmune response to viruses and also increased oxidative stress in
atients [38,39].
There are several limitations of this retrospective study. Firstly,
he cross-sectional nature of our study lacks the advantage of
ollow-up in a longitudinal study to see the course of the disease.
oreover, although we summarized the clinical characteristics for
ild and moderate cases of COVID-19, there is still a lack of a
rediction model for disease severity progression, and also case
atality, since none of our patients had severe COVID-19 and none
ad died. Secondly, lymphopenia and other lab values are com-
on  in COVID-19 patients and have been reported in other studies
ublished elsewhere in the world. Therefore, it would be useful
f we  could also consider doing a study with the laboratory and
adiological findings in COVID-19.
onclusion
We tried to assess the burden of COVID-19 in patients in Saudi
rabia by analyzing their clinical characteristics. The most com-
on  presenting symptoms were cough, fever, and fatigue for mild
o moderate COVID-19 patients. Sputum production and different
omorbidities including hypertension and diabetes were predom-
nantly seen in the older age group. Remarkably, patients with a
istory of hypertension had a lesser length of stay and were less
ikely to present with shortness of breath, cough, sputum, and fever.
urther larger collaborative national studies are essential to under-






























younger ages. Lancet 2020;395(10236):1544–5.
[38] Unterborn J. Pulmonary function testing in obesity, pregnancy, and extremesARTICLEJIPH-1442; No. of Pages 6
A. Al-Omari et al. 
will eventually help in more effectively controlling the spread of






The study was approved by Dr. Sulaiman Al Habib Medical Group
Institutional Review Board, reference number (RC20.04.79).
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